control trial intraven immunoglobulin chronic fatigu syndrom purpos establish therapi chronic fatigu syndrom cf ill varieti immunolog abnorm hypothesi chronic viral infect immunoregulatori defect pathogenesi cf therapeut benefit intraven immunoglobulin IV igg group patient cf serum immunoglobulin concentr peripher blood lymphocyt subset number outset studi effect IV igg therapi igg subclass level patient method thirti patient cf double-blind placebo-control trial IV igg treatment regimen IV igg g/kg intraven placebo albumin solut day month particip self-assess form treatment sever symptom function statu health percept patient advers experi worsen symptom hour treatment result twenty-eight patient trial baselin patient moder fatigu measur social function health percept mark impair low level low level end studi signific therapeut benefit term symptom amelior improv function statu restor level normal rang major advers experi IV igg placebo group conclus result studi IV igg unlik clinic benefit cf addit need placebo-control trial candid therapi cf research effort etiolog pathogenesi disord 